A Phase 1, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Patients with Human Immunodeficiency Virus-1 Infection.

Trial Profile

A Phase 1, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Patients with Human Immunodeficiency Virus-1 Infection.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs BIT 225 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 29 Nov 2015 Results published in the Journal of Antimicrobial Chemotherapy
    • 03 Jul 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
    • 02 Jul 2013 Phase 2 results to be presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment, according to a Biotron media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top